Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Payables (2022 - 2025)

Praxis Precision Medicines has reported Payables over the past 4 years, most recently at $24.6 million for Q4 2025.

  • Quarterly results put Payables at $24.6 million for Q4 2025, up 96.58% from a year ago — trailing twelve months through Dec 2025 was $24.6 million (up 96.58% YoY), and the annual figure for FY2025 was $24.6 million, up 96.58%.
  • Payables for Q4 2025 was $24.6 million at Praxis Precision Medicines, down from $30.8 million in the prior quarter.
  • Over the last five years, Payables for PRAX hit a ceiling of $30.8 million in Q3 2025 and a floor of $5.8 million in Q4 2023.
  • Median Payables over the past 4 years was $12.9 million (2022), compared with a mean of $15.0 million.
  • Biggest five-year swings in Payables: tumbled 60.37% in 2023 and later skyrocketed 251.82% in 2025.
  • Praxis Precision Medicines' Payables stood at $14.7 million in 2022, then tumbled by 60.37% to $5.8 million in 2023, then skyrocketed by 115.44% to $12.5 million in 2024, then soared by 96.58% to $24.6 million in 2025.
  • The last three reported values for Payables were $24.6 million (Q4 2025), $30.8 million (Q3 2025), and $28.8 million (Q2 2025) per Business Quant data.